Clinical Trial Update: Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating myeloablative haploidentical bone marrow transplantation with post-transplant cyclophosphamide in pediatric patients with hematologic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Hematologic Malignancies in Children

Drugs mentioned

• haploidentical bone marrow transplant
• post-transplant cyclophosphamide (cyclophosphamide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Myeloablative Conditioning, HLA-mismatched Bone Marrow Transplantation | Phase 2 | Status: COMPLETED | Results posted: 2019-04-18